Cronos Group (NASDAQ:CRON - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $45.73 million for the quarter.
Cronos Group (NASDAQ:CRON - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.01. Cronos Group had a net margin of 39.69% and a negative return on equity of 0.07%. The business had revenue of $33.62 million during the quarter, compared to the consensus estimate of $45.44 million. On average, analysts expect Cronos Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Cronos Group Trading Down 1.5%
Shares of CRON stock traded down $0.03 during trading hours on Friday, reaching $1.95. 2,314,574 shares of the company's stock were exchanged, compared to its average volume of 1,278,106. Cronos Group has a 1 year low of $1.60 and a 1 year high of $2.46. The stock has a market cap of $752.08 million, a PE ratio of 15.00 and a beta of 1.01. The stock's fifty day moving average price is $1.99 and its two-hundred day moving average price is $1.93.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the stock. Envestnet Asset Management Inc. purchased a new stake in Cronos Group in the 2nd quarter valued at $36,000. Jones Financial Companies Lllp grew its holdings in shares of Cronos Group by 291.6% during the 1st quarter. Jones Financial Companies Lllp now owns 65,099 shares of the company's stock worth $118,000 after purchasing an additional 48,476 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in Cronos Group by 84.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,076,405 shares of the company's stock valued at $1,948,000 after acquiring an additional 493,161 shares during the period. 8.71% of the stock is owned by institutional investors and hedge funds.
Cronos Group Company Profile
(
Get Free Report)
Cronos Group Inc operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands.
See Also

Before you consider Cronos Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cronos Group wasn't on the list.
While Cronos Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.